Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968 to Filter to 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968

---

Search results

• Journal article
  van Manen MJG, Wu Z, Molyneaux PL, Wijsenbeek MSet al., 2025,

  Chronic cough and interstitial lung disease

  , Ers Monograph, Vol: 2025-December, Pages: 206-224, ISSN: 2312-508X

  Cough is a common and burdensome symptom in interstitial lung disease (ILD), particularly IPF. It has a profound impact on quality of life and is associated with disease progression and poorer prognosis. This chapter outlines its epidemiology, pathophysiology, assessment and management. Underlying mechanisms include structural distortion, neurogenic inflammation and sensory pathway sensitisation, with comorbidities such as gastro-oesophageal reflux and obstructive sleep apnoea contributing to symptom burden. Evaluation of cough includes both subjective and objective measures. Management focuses on treatable traits, with speech and behavioural therapy showing benefit. Pharmacological options remain limited; however, opioids have demonstrated efficacy and new therapies are emerging. In non-IPF ILD, immunosuppressants may reduce cough, though evidence is mixed. Future research should aim to standardise outcome measures, enrich study populations and clarify whether cough acts as a driver or marker of disease progression.

  • Abstract
  • Cite
• Journal article
  Kim JS, Pugashetti J, Ma S-F, Huang Y, Podolanczuk AJ, Lynch DA, Oh A, Mychaleckyj J, Manichaikul A, Rich S, Chua F, Adams TM, Flaherty KR, Lee JS, Lasky JA, Raghu G, Murray S, Spino C, Martinez FJ, Noth I, Humphries SM, Adegunsoye A, Molyneaux PL, Oldham JM, Newton CAet al., 2025,

  Associations of interstitial lung disease subtype and CT pattern with lung function and survival

  , Thorax, Vol: 80, Pages: 927-934, ISSN: 0040-6376

  Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, epidemiological data with longitudinal sampling and replication remains lacking.Methods Data was used from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR) (n=932) and a meta-cohort of ILD research studies (n=1579). Linear mixed-effects models and Cox proportional hazard models were used to determine forced vital capacity (FVC) slopes and 5-year transplant-free survival, respectively, by ILD diagnosis and UIP radiological pattern. Secondarily, we examined FVC and survival by diagnosis and radiological fibrosis quantified by data-driven texture analysis (DTA) in the PFF-PR. Models were adjusted for age, sex, smoking and antifibrotic and immunosuppression medication use.Results The proportions of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP) and connective tissue disease (CTD)-ILD were the following for PFF-PR (70%, 11%, 19%) and meta-cohort (21%, 32%, 47%). In the PFF-PR, CTD-ILD with UIP CT pattern was associated with slower FVC decline (−34.4 mL/year) compared with IPF (−158.4 mL/year) and longer transplant-free survival (HR 0.50, 95% CI 0.29 to 0.85). This was replicated in the meta cohort for FVC (−53.1 vs −185.9 mL/year, p<0.0001) and survival (HR 0.38, 95% CI 0.27 to 0.53). A similar pattern was seen using DTA to objectively categorise patients into higher and lower radiological fibrosis. Between IPF and FHP-UIP, FVC decline was not significantly different in the PFF-PR (−203.4 vs −158.4 mL/year, p=0.58) and meta-cohort (−124.0 vs −185.9 mL/year, p=0.25).Conclusions Even in the presence of a UIP CT pattern, there may still be differences in lung function over time and survival, particularly for CTD-ILD.

  • Abstract
  • Cite
• Journal article
  Lee CT, Ghandi SA, Elmrayed S, Barnes H, Lorenzetti D, Salibury ML, Stewart ID, Barber C, Peters CE, Feary J, Johannson KAet al., 2025,

  Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis

  , Thorax, Vol: 80, Pages: 918-926, ISSN: 0040-6376

  Rationale: Inhalational exposures are associated with risk of developing interstitial lung disease (ILD), yet the relationship between specific exposures and ILD is poorly characterized. Objective: Identify inhalational exposures associated with ILD and estimate the effects of exposures on ILD risk.Methods: MEDLINE and EMBASE databases were searched from 1990 until 2022 to identify inhalational exposures associated with ILD diagnosis. ILDs where causality is well-established (hypersensitivity pneumonitis, pneumoconiosis) and sarcoidosis were excluded. Two independent reviewers screened abstracts with full-text review and data extraction of eligible studies. Where possible, data were pooled and multi-level meta-analysis was specified using a random effects model. Sources of heterogeneity and risk of bias were assessed. Main Results: Ninety-six studies were included in the systematic review, representing 40,819,116 subjects (295,167 had ILD, 40,523,949 controls). For the meta-analysis, fifty-four studies were included (40,490,793 subjects: 273,899 ILD, 40,216,894 controls). Exposures associated with significantly increased ILD risk included smoking (OR 1.69, 95% CI 1.47-1.94), organic exposures (OR 1.56, 95% CI 1.12-2.16), metals (OR 1.52, 95% CI 1.07-2.16), dust (OR 1.45, 95% CI 1.20-1.76), and asbestos (OR 1.53, 95% CI 1.08-2.15). Silica and fumes had positive associations with ILD that trended toward significance. Conclusions: This systematic review and multilevel meta-analysis is the first to comprehensively assess the effect of inhalational exposures on overall risk of ILD, with multiple putative exposures identified. Future work should investigate novel occupational exposures associated with ILD, characterize the gene-environment interaction, and develop preventative strategies.

  • Abstract
  • Cite
• Journal article
  Sim-Devadas AL, Soon SBS, Lakshmanan EM, Jain R, Chotirmall SH, Manski-Nankervis JAet al., 2025,

  OPENing the door for patient and public involvement in medical research in Singapore

  , Research Involvement and Engagement, Vol: 11

  Patient and public involvement (PPI) in research in Singapore is developing. In the last 10 years, there has been strong growth in patient advocacy and support groups and increasing interest in contributing to research. In recognition of the positive benefits of PPI to generate high quality research that matters to patients and the community, the Lee Kong Chian School of Medicine launched the Office of Patient Engagement, otherwise known as OPEN. OPEN has developed training workshops and networking opportunities for researchers and patients, developed the Patient Voices community and held its first symposium in November 2024. OPEN is collaborating with the Singapore Clinical Research Institute, healthcare clusters and Universities across Singapore with the aim of expanding training, developing culturally appropriate PPI guidance and undertaking research to understand how to best implement PPI in the Asian setting.

  • Abstract
  • Cite
• Journal article
  Sun M, Zhao Y, Ledesma-Amaro R, Gao J, Liu X, Bai Z, Gao AX, Wang Pet al., 2025,

  Engineered membraneless organelles in Corynebacterium glutamicum for enhanced indigoidine biosynthesis and antimicrobial peptide production

  , Synthetic and Systems Biotechnology, Vol: 10, Pages: 1331-1340, ISSN: 2405-805X

  Liquid-liquid phase separation (LLPS)-driven membraneless organelles (MLOs) have been employed to enhance metabolic efficiency in various microbial cell factories. However, their application in the industrial bacterium Corynebacterium glutamicum has not been explored. Here, we report the formation of liquid protein condensates in C. glutamicum using the RGG domain of Caenorhabditis elegans LAF-1. We optimized conditions for condensate formation, including the pre-induction period, inducer concentration, and cultivation temperature. Using the indigoidine biosynthesis pathway as a model, we demonstrated that LLPS-mediated MLOs enhanced indigoidine production. Furthermore, we applied these MLOs to modulate the toxicity of antimicrobial peptides (AMPs) to host cells, facilitating the expression of AMPs, including melittin and lactoferricin B. These findings provide insights into MLOs engineering in C. glutamicum and suggest broader applications of LLPS-mediated systems in industrial biotechnology.

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Mayer-Hamblett N, Kerper NR, Clancy JP, Davies JC, Taylor-Cousar JL, Donaldson SH, Bell SC, Jain R, Simmonds NJ, Mall MA, Goss CH, Rayment JH, Setiawan L, Pilewski JMet al., 2025,

  Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials

  , LANCET RESPIRATORY MEDICINE, Vol: 13, ISSN: 2213-2600
  • Cite
• Journal article
  Piciucchi S, Adegunsoye A, Travis WD, Nicholson AG, Wells AU, Cooper WA, Khor YH, Wijsenbeek MS, Sharma A, Hariri LP, Antoniou K, Borie R, Fabre A, Inoue Y, Johannson KA, Johkoh T, Kawano-Dourado L, Kazerooni E, Maher TM, Molyneaux PL, Protti R, Ravaglia C, Renzoni EA, Saito-Koyama R, Sverzellati N, Walsh SLF, Wolters PJ, Yang S-R, Ryerson CJet al., 2025,

  Reply: The rationale for distinguishing RB-ILD and AMP

  , EUROPEAN RESPIRATORY JOURNAL, Vol: 66, ISSN: 0903-1936
  • Cite
• Journal article
  Chalmers JD, Haworth CS, Flume P, Long MB, Burgel P-R, Dimakou K, Blasi F, Herrero-Cortina B, Dhar R, Chotirmall SH, Ringshausen FC, Altenburg J, Morgan L, Nigro M, Crichton ML, Van Meel C, Sibila O, Timothy A, Kompatsiari E, Hedberg T, Vandendriessche T, McShane PJ, Tonia T, Winthrop K, Loebinger MR, Lorent N, Goeminne P, Shteinberg M, Polverino E, Aliberti Set al., 2025,

  European Respiratory Society clinical practice guideline for the management of adult bronchiectasis.

  , Eur Respir J, Vol: 66

  BACKGROUND: Bronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis. METHODS: A European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of eight PICO (Patients, Intervention, Comparator, Outcomes) questions and three narrative questions were developed. RECOMMENDATIONS: The Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis, and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long-term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations and managing the deteriorating patient. CONCLUSION: T

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Ryerson CJ, Adegunsoye A, Piciucchi S, Hariri LP, Khor YH, Wijsenbeek MS, Wells AU, Sharma A, Cooper WA, Antoniou K, Borie R, Fabre A, Inoue Y, Johannson KA, Johkoh T, Kawano-Dourado L, Kazerooni E, Maher TM, Molyneaux PL, Protti R, Ravaglia C, Renzoni EA, Saito-Koyama R, Sverzellati N, Walsh SLF, Wolters PJ, Yang S-R, Travis WD, Nicholson AGet al., 2025,

  Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis

  , EUROPEAN RESPIRATORY JOURNAL, Vol: 66, ISSN: 0903-1936
  • Cite
• Journal article
  Narayana JK, Ling YKW, Mac Aogain M, Chotirmall SHet al., 2025,

  Characterising research trends in bronchiectasis through AI-powered analytics

  , EUROPEAN RESPIRATORY JOURNAL, Vol: 66, ISSN: 0903-1936
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.